238 related articles for article (PubMed ID: 21748294)
21. Breast cancer susceptibility variants alter risks in familial disease.
Latif A; Hadfield KD; Roberts SA; Shenton A; Lalloo F; Black GC; Howell A; Evans DG; Newman WG
J Med Genet; 2010 Feb; 47(2):126-31. PubMed ID: 19617217
[TBL] [Abstract][Full Text] [Related]
22. [Associations between TOX3 rs3803662 polymorphisms and immunological markers of breast cancer].
Chen Q; He Y; Liu C; Liu H; Sun X; Shao Y; Huang T; Xu B
Zhonghua Yi Xue Za Zhi; 2015 Sep; 95(34):2783-6. PubMed ID: 26711978
[TBL] [Abstract][Full Text] [Related]
23. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.
Varadi V; Brendle A; Brandt A; Johansson R; Enquist K; Henriksson R; Svenson U; Tavelin B; Roos G; Hemminki K; Lenner P; Försti A
Eur J Cancer; 2009 Nov; 45(17):3008-16. PubMed ID: 19766477
[TBL] [Abstract][Full Text] [Related]
25. The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.
van Gils CH; Onland-Moret NC; Roest M; van Noord PA; Peeters PH
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1194-9. PubMed ID: 14652280
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
27. Association of heparanase gene (HPSE-1) single nucleotide polymorphisms with gastric cancer.
Yue Z; Song Y; Wang Z; Luo Y; Jiang L; Xing L; Xu H; Zhang X
J Surg Oncol; 2010 Jul; 102(1):68-72. PubMed ID: 20578081
[TBL] [Abstract][Full Text] [Related]
28. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
Long JR; Kataoka N; Shu XO; Wen W; Gao YT; Cai Q; Zheng W
Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2115-22. PubMed ID: 17119036
[TBL] [Abstract][Full Text] [Related]
30. Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients.
Vaclavikova R; Nordgard SH; Alnaes GI; Hubackova M; Kubala E; Kodet R; Mrhalova M; Novotny J; Gut I; Kristensen VN; Soucek P
Pharmacogenet Genomics; 2008 Mar; 18(3):263-73. PubMed ID: 18300948
[TBL] [Abstract][Full Text] [Related]
31. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer.
Naidu R; Har YC; Taib NA
J Exp Clin Cancer Res; 2007 Mar; 26(1):133-40. PubMed ID: 17550142
[TBL] [Abstract][Full Text] [Related]
32. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression.
Lei H; Hemminki K; Altieri A; Johansson R; Enquist K; Hallmans G; Lenner P; Försti A
Breast Cancer Res Treat; 2007 May; 103(1):61-9. PubMed ID: 17033924
[TBL] [Abstract][Full Text] [Related]
33. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis.
Försti A; Jin Q; Altieri A; Johansson R; Wagner K; Enquist K; Grzybowska E; Pamula J; Pekala W; Hallmans G; Lenner P; Hemminki K
Breast Cancer Res Treat; 2007 Jan; 101(1):83-93. PubMed ID: 16807673
[TBL] [Abstract][Full Text] [Related]
35. Endostatin gene variation and protein levels in breast cancer susceptibility and severity.
Balasubramanian SP; Cross SS; Globe J; Cox A; Brown NJ; Reed MW
BMC Cancer; 2007 Jun; 7():107. PubMed ID: 17587451
[TBL] [Abstract][Full Text] [Related]
36. Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians.
Shan J; Mahfoudh W; Dsouza SP; Hassen E; Bouaouina N; Abdelhak S; Benhadjayed A; Memmi H; Mathew RA; Aigha II; Gabbouj S; Remadi Y; Chouchane L
Breast Cancer Res Treat; 2012 Oct; 135(3):715-24. PubMed ID: 22910930
[TBL] [Abstract][Full Text] [Related]
37. LFA-1 gene polymorphisms are associated with the sporadic infiltrative duct breast carcinoma in Chinese Han women of Heilongjiang Province.
Fu Z; Jiao M; Zhang M; Xu F; Yuan W; Pang D; Li D
Breast Cancer Res Treat; 2011 May; 127(1):265-71. PubMed ID: 20953905
[TBL] [Abstract][Full Text] [Related]
38. Low-penetrance susceptibility variants and postmenopausal oestrogen receptor positive breast cancer.
Özgöz A; İçduygu FM; Yükseltürk A; ŞamlI H; Öztürk KH; Başkan Z
J Genet; 2020; 99():. PubMed ID: 32366738
[TBL] [Abstract][Full Text] [Related]
39. The role of genetic breast cancer susceptibility variants as prognostic factors.
Fasching PA; Pharoah PD; Cox A; Nevanlinna H; Bojesen SE; Karn T; Broeks A; van Leeuwen FE; van't Veer LJ; Udo R; Dunning AM; Greco D; Aittomäki K; Blomqvist C; Shah M; Nordestgaard BG; Flyger H; Hopper JL; Southey MC; Apicella C; Garcia-Closas M; Sherman M; Lissowska J; Seynaeve C; Huijts PE; Tollenaar RA; Ziogas A; Ekici AB; Rauh C; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Andrulis IL; Ozcelik H; Mulligan AM; Glendon G; Hall P; Czene K; Liu J; Chang-Claude J; Wang-Gohrke S; Eilber U; Nickels S; Dörk T; Schiekel M; Bremer M; Park-Simon TW; Giles GG; Severi G; Baglietto L; Hooning MJ; Martens JW; Jager A; Kriege M; Lindblom A; Margolin S; Couch FJ; Stevens KN; Olson JE; Kosel M; Cross SS; Balasubramanian SP; Reed MW; Miron A; John EM; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Kauppila S; Burwinkel B; Marme F; Schneeweiss A; Sohn C; Chenevix-Trench G; ; Lambrechts D; Dieudonne AS; Hatse S; van Limbergen E; Benitez J; Milne RL; Zamora MP; Pérez JI; Bonanni B; Peissel B; Loris B; Peterlongo P; Rajaraman P; Schonfeld SJ; Anton-Culver H; Devilee P; Beckmann MW; Slamon DJ; Phillips KA; Figueroa JD; Humphreys MK; Easton DF; Schmidt MK
Hum Mol Genet; 2012 Sep; 21(17):3926-39. PubMed ID: 22532573
[TBL] [Abstract][Full Text] [Related]
40. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
